MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2022 International Congress

September 15-18, 2022. Madrid, Spain.

View by Title View Categories
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Safety and Efficacy of Verdiperstat, a Novel Myeloperoxidase Inhibitor, in MSA

    I. Qureshi, V. Wirtz, L. Brady, J. Ellison, A. Ellenbogen, R. Freeman, G. Höglinger, H. Kaufmann, A. Lang, P. Low, W. Meissner, P. Millar Vernetti, H. Morris, J. Palma, S. Perlman, W. Poewe, J. Schmahmann, K. Seppi, W. Singer, S. Vernino, G. Wenning (New Haven, USA)

  • Safety and Tolerability of Apomorphine Sublingual Film and Subcutaneous Apomorphine for the Treatment of OFF Episodes in Parkinson’s Disease

    O. Rascol, W. Poewe, F. Stocchi, R. Chaudhuri, J. Kassubek, L. Lopez Manzanares, V. Leta, I. Zhang, A. Bowling, S. Wu, E. Pappert (Toulouse, France)

  • Safety and tolerability of Nilotinib in patients with Huntington’s disease

    K. Anderson (Washington, USA)

  • Safety of incobotulinumtoxinA in pediatrics: A pooled analysis

    F. Heinen, M. Banach, E. Dabrowski, D. Gaebler-Spira, H. Chambers, S. Schroeder, T. Geister, M. Althaus, A. Hanschmann, S. Berweck (Munich, Germany)

  • Safety of opicapone after 5 years of post-marketing experience worldwide

    L. Guedes, J. Graça, M. Sampaio, M. Vieira, F. Rocha, H. Gama (Coronado, Portugal)

  • Safety, Target Engagement and Effects of Bosutinib in Dementia with Lewy Bodies

    F. Pagan, Y. Torres-Yaghi, M. Hebron, R. Turner, B. Wilmarth, S. Matar, D. Ferrante, J. Ahn, C. Moussa (Washington, USA)

  • Safinamide adherence: the experience of the movement disorder unit of Trieste.

    M. Catalan, M. Liccari, V. Tommasini, L. Antonutti, P. Manganotti (Trieste, Italy)

  • Safinamide as an adjunct to Levodopa Therapy in Asian and Caucasian Patients with Parkinson’s Disease and Motor Fluctuations: A post-hoc Analysis of the SETTLE study

    R. Bhidayasiri, T. Ishida, RE. Husni, T. Kamei, I. Suzuki, SL. Wu, JW. Cho (Bangkok, Thailand)

  • SAFINAMIDE: REAL LIFE STUDY. EFFICACY IN SWITCH FROM RASAGILINA AND LOW-DOSE TREATMENT.

    MI. Morales-Casado, N. López-Ariztegui, DD. García-Meléndez, A. Diezma-Martín (Toledo, Spain)

  • Sarcopenia Screening with Limb Circumference and Impacts of Sarcopenia in Parkinson’s disease

    SJ. Kim, YJ. Jeong, SM. Cheon ()

  • « Previous Page
  • 1
  • …
  • 121
  • 122
  • 123
  • 124
  • 125
  • …
  • 153
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • #22901 (not found)
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • An atypical and interesting feature of Parkinson´s disease
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley